A Systematic Population-Based Approach to Identify Patients With NTRK Gene Fusion-Positive and RET Gene Fusion/Mutation-Positive Thyroid Cancers Who Could Benefit from Treatment With TRK or RET Inhibitors

Abstract

We aimed to identify NTRK or RET gene fusion/mutation-positive patients who could benefit from larotrectinib, entrectinib or selpercatinib. Patients with metastatic thyroid cancer and ATA high recurrence risk in Southern Alberta were “pre-screened” with MassARRAY® BRAF test, colon panel, melanoma panel, or ThyroSPEC™ with different coverage. Tumours negative for interrogated mutations were “screened” for NTRK gene fusions and RET gene fusions/mutations with the Oncomine™ Comprehensive Assay v3 (OCAv3).